Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF

Cystic Fibrosis Clinical Trial

— MRIinfantCF  

Official title:

MRI Predictors of Infection, Inflammation, and Structural Lung Damage in CF (Cystic Fibrosis)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01832519
• Other study ID #: CIN001InfantMRI
• Secondary ID: R457-CR11_01R01H
• Status: Completed
• Phase: N/A
• First received: April 8, 2013
• Last updated: August 21, 2017
• Start date: February 2013
• Est. completion date: January 9, 2017

Study information

• Verified date: August 2017
• Source: Children's Hospital Medical Center, Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Our research is comparing the lungs of babies and young children with CF (cystic fibrosis) to those without CF. We are looking at the blood flow in the lungs to help doctors better understand how CF damages lungs and how to prevent this damage in the future. We will use MRI (Magnetic Resonance Imaging) and special blood tests as ways to understand early changes in the lungs of babies and young children with CF. We will look at the special blood tests to see if they can work as signals for the doctors to better understand when changes are happening in the lungs.

For the babies with CF, we will compare MRI images of the lungs to their CT images (also sometimes called CAT scans or Computerized Tomography). We hope that this study will help us reduce the number of X-rays and CT scans children with CF might get in the future. Because MRI's do not use radiation, this could reduce the amount of radiation exposure that children with CF would get over their lifetime.

Description:

Cystic fibrosis (CF) is a well characterized multi-organ disease producing mucus obstruction, chronic lung infection, inflammation, and oxidant stress. These processes result in airway damage, chronic pulmonary symptoms, and ultimately death in young adulthood. These processes are largely silent in the infant and toddler CF population, and ultimately result in lung damage and symptoms of CF. Detection and monitoring of lung disease in infants and toddlers with CF is currently limited, and is a major barrier to advancements in care and research for this population.

This study will be performed in CF and non-CF controls age 6 months - 4.5 years, with repeated measures in CF patients over this window. We intend to examine new techniques to evaluate the lung of CF infants based on magnetic resonance imaging (MRI) that incorporates measurements of lung structure and blood flow. In the CF group, we will augment MRI images with CT images to determine structural relationships between MR and CT (a gold standard to assess lung structure in CF). We will correlate imaging data with core peripheral biomarkers of CF using an unbiased, metabolomic and proteomic-based approach. It is hoped that the results of this study will provide support for the use of MRI to monitor lung structure and blood flow in early CF lung disease, potentially providing a modality to monitor disease status independent of radiation exposure.

We hypothesize that MRI of the lung and pulmonary circulation has the potential to serve as a sensitive and portable tool to monitor early CF lung disease. We will examine three functional aspects of pulmonary blood flow (total and regional pulmonary perfusion, vascular resistance, and aortopulmonary collateral blood flow) compared with structural assessment of the lung by MRI and CT.

This proposal couples advancements in magnetic resonance imaging (MRI) techniques with the emerging technologies of metabolomics and proteomics, linking new MR imaging to candidate and novel pathway analysis. We will use the new technologies (metabolomics and proteomics - performed on peripheral blood samples) to determine if altered signaling pathways detected in the blood are related to changes in the lung. We hypothesize that changes in pulmonary perfusion and/or structure can be correlated with peripheral biomarkers identified by metabolomics and proteomic methodology.

Candidate metabolomic pathways that have been shown to segregate CF from non-CF conditions (including oxidative status, purinergic signaling, and glucose metabolism) will be the focus of initial biomarker analysis, with advanced bioinformatic techniques applied to define novel relationships between the metabolome and imaging. Proteomics will serve a validating function, helping to assign enzyme pathways to metabolomics alterations.

The study design includes 30 CF subjects divided into 2 age groups (6 to 12 month old and 24 to 36 month old) who will receive chest CT and High Resolution CT (HRCT) at baseline and 12 months later. They will be compared to 30 age matched non-CF subjects who will have one visit of MRI with contrast. The non-CF group only includes subjects scheduled for MRI for clinical reasons and will have an additional chest imaging at the end of their scheduled MRI. Both groups will have blood drawn to measure metabolomic and proteomic markers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 9, 2017
• Est. primary completion date: January 9, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 52 Months

Eligibility

Inclusion criteria:

CF

• Age at enrollment 6 to 12 months or 24 to 52 months.

• Diagnosed with two CF-causing mutations ('severe' mutations, classes 1, 2, or 3).

Non-CF

• Age at enrollment 6 months to 52 months

• Clinically scheduled for MRI neuroimaging

• Negative history of renal abnormalities

Exclusion criteria:

CF

• Pulmonary exacerbation

• Any known intracardiac defects

• Serum creatinine > 1.5 times the upper limit of normal for age

• Cystatin C > 0.53 (cutoff for normal range)

Non-CF

• Active lung disease as determined by assessment of anesthesiologist

• Any known intracardiac defects

• Results of the most recent serum creatinine within past 12 months above normal range for age

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Locations

Country	Name	City	State
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Children's Hospital Medical Center, Cincinnati	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pulmonary blood flow	Comparison of pulmonary blood flow will be done between MRI pair matched subjects.	CF: Baseline and 1 year; Control: Baseline
Secondary	comparison of lung structure by MRI and CT	On CF cohort, comparison of CT to MRI.	Baseline and one year